Y-Biologics, Inc
Develops novel antibody cancer therapies using proprietary T-cell engager & antibody library tech.
338840 | KO
Overview
Corporate Details
- ISIN(s):
- KR7338840002
- LEI:
- Country:
- South Korea
- Address:
- 대전광역시 유성구 테크로 4로 17, 비715호, 대전광역시
- Website:
- https://ybiologics.com/en/
- Sector:
- Mining and quarrying
- Industry:
- Mining of non-ferrous metal ores
Description
Y-Biologics, Inc. is a biopharmaceutical company established in 2007, specializing in the research and development of novel antibody therapeutics. The company's core R&D is driven by its proprietary platform technologies. These include Ymax®-ABL, a fully human antibody library that serves as the foundation for its discovery process, and ALiCE (Antibody-Like Cell Engager), a globally patented bispecific T-cell engager platform. The ALiCE technology creates Y-shaped molecules designed to simultaneously bind to cancer cells and T-cells, thereby activating the T-cells to directly eliminate tumors. Y-Biologics' pipeline features immuno-oncology candidates such as YBL-006, an anti-PD-1 antibody, and YBL-013, an ALiCE-based therapeutic. The company's business model involves both in-house development and open innovation through joint research and technology licensing partnerships with global pharmaceutical firms.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2025-09-10 00:00 |
Post-Annual General Meeting Information
임시주주총회결과
|
Korean | 7.4 KB | ||
| 2025-08-26 00:00 |
Pre-Annual General Meeting Information
[기재정정]주주총회소집결의 (임시주주총회)
|
Korean | 12.4 KB | ||
| 2025-08-26 00:00 |
Pre-Annual General Meeting Information
주주총회소집공고
|
Korean | 57.0 KB | ||
| 2025-08-14 00:00 |
Interim Report
반기보고서 (2025.06)
|
Korean | 1.1 MB | ||
| 2025-08-14 00:00 |
Major Shareholding Notification
주식등의대량보유상황보고서(약식)
|
Korean | 60.0 KB | ||
| 2025-08-07 00:00 |
Share Issue/Capital Change
증권발행결과(자율공시) (제1회차 CB)
|
Korean | 5.6 KB | ||
| 2025-07-30 00:00 |
Capital/Financing Update
주요사항보고서(전환사채권발행결정)
|
Korean | 107.3 KB | ||
| 2025-07-30 00:00 |
Pre-Annual General Meeting Information
주주총회소집결의 (임시주주총회)
|
Korean | 7.1 KB | ||
| 2025-07-30 00:00 |
Pre-Annual General Meeting Information
주주명부폐쇄기간또는기준일설정
|
Korean | 4.2 KB | ||
| 2025-07-15 00:00 |
Regulatory News Service
투자판단관련주요경영사항 ([국책과제 선정] 글로벌 시장 진출형 다중항체의 품질 맞춤형 생산공정 기술 개발)
|
Korean | 8.6 KB | ||
| 2025-07-01 00:00 |
Regulatory News Service
투자판단관련주요경영사항 ([국책과제 선정] 면역함암 항체의약품의 저항성 및 불응성 한계 극복을 위한 이중항체-사이토카인…
|
Korean | 9.5 KB | ||
| 2025-05-27 00:00 |
Share Issue/Capital Change
전환주식의전환청구권행사
|
Korean | 15.3 KB | ||
| 2025-05-14 00:00 |
Quarterly Report
분기보고서 (2025.03)
|
Korean | 970.8 KB | ||
| 2025-05-13 00:00 |
M&A Activity
투자판단관련주요경영사항 (신규 항체-약물 결합체(ADC) 연구개발을 위한 항체 기술이전 계약 체결)
|
Korean | 11.2 KB | ||
| 2025-04-30 00:00 |
Report Publication Announcement
기업설명회(IR)개최
|
Korean | 6.8 KB |
Automate Your Workflow. Get a real-time feed of all Y-Biologics, Inc filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Y-Biologics, Inc
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Y-Biologics, Inc via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
